Mantle cell lymphoma: a Turkish Multi-Center Study.

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Mantle Cell Lymphoma (MCL) is a rare B-cell neoplasm characterized by the CCND1 translocation.
• Treatment guidelines for MCL vary based on patient factors like age and comorbidities.
• Understanding prognostic factors is crucial for improving survival outcomes in MCL.

Purpose of the Study:

• To analyze the clinical features of 78 MCL patients.
• To evaluate prognostic factors influencing overall survival (OS) and disease-free survival (DFS) in MCL.
• To identify independent predictors of survival in MCL.

Main Methods:

• Retrospective analysis of 78 MCL patients from two Hematology Departments (January 2001 - September 2018).
• Evaluation of treatment regimens including R-CHOP, R-Bendamustine, HyperCVAD, and R-CHOP/R-DHAP.
• Statistical analysis including univariate and multivariate analyses to identify prognostic factors.

Main Results:

• Median patient age was 62 years, with 78.2% males.
• R-CHOP was the most frequent first-line treatment (42.3%).
• Higher neutrophil counts at diagnosis were an independent negative prognostic factor for OS (p=0.005), with median OS of 14.8 months vs. 77.8 months for lower counts (p=0.001).

Conclusions:

• MCL remains an incurable disease, although median OS has improved with new therapies.
• R-CHOP is a common first-line treatment for MCL.
• Elevated neutrophil count at diagnosis is a significant adverse prognostic factor for overall survival in MCL.